São Paulo Drug Prices Vary Wildly: Procon Research Finds 25x Difference Between Stores
A recent survey by Procon, São Paulo's consumer protection agency, has revealed significant price discrepancies for the same medications across different pharmacies in the city. The research, which examined ten pharmacy chains, found that the identical drug can cost up to 25 times more depending on the store. These price variations are particularly pronounced in the city's South Zone. For instance, the circulation medication tadalafil was found priced at R$3.87 in one South Zone store and R$98 in a North Zone location. Similarly, the allergy medication loratadine showed a price difference from R$1.98 to R$22.36. The anti-inflammatory nimesulide was observed to be 11 times more expensive between different outlets. Procon-SP's executive director, Luiz Orsatti Filho, highlighted that generic drugs are, on average, 60% cheaper than their reference counterparts, offering substantial savings for consumers. While price comparison remains crucial, the agency acknowledges that individuals with reduced mobility may face challenges in physically visiting multiple stores. Online purchasing is presented as a viable alternative, with generally lower prices and smaller variations between e-commerce sites. Online generic drugs were found to be 20.58% cheaper on average, and reference drugs 8.13% cheaper. However, even online, significant differences persist, such as the blood pressure medication sildenafil citrate being sold for R$0.89 on one website and R$11.90 on another. The research also noted that medication prices increased above inflation between 2025 and 2026, with generics rising 12.74% and reference drugs 8.43%, compared to a general inflation rate of 4.99%. Importantly, no pharmacy exceeded the maximum price ceiling set by the federal government, operating within free market competition rules.
This Procon research highlights a significant market inefficiency in São Paulo's pharmaceutical sector, where price dispersion for essential goods far exceeds typical retail variations. While operating within legal pricing ceilings, the wide price gaps suggest that information asymmetry and consumer search costs are substantial barriers to competitive pricing. The findings underscore the potential for advanced digital platforms and data aggregation services to bridge this information gap, potentially leading to more consistent pricing and improved consumer welfare, especially for vulnerable populations. Looking ahead, the interplay between regulatory price controls, market competition, and the increasing digitalization of retail will continue to shape access and affordability of healthcare products, presenting both opportunities for efficiency gains and risks of exacerbating existing inequalities if not managed thoughtfully.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.